<DOC>
	<DOCNO>NCT00500058</DOCNO>
	<brief_summary>The purpose identify dose SB-485232 safe , tolerable effective use combination Rituximab patient non-Hodgkin 's lymphoma ( NHL ) . This study use standard treatment regimen Rituximab combination rise dos SB-485232 . The dose select study use future study .</brief_summary>
	<brief_title>A Phase I , Dose-Escalation Study Assess Safety Biological Activity Recombinant Human Interleukin-18</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm diagnosis subtype CD20+ B cell NHL . Subjects must disease progressed standard therapy effective standard therapy ( include highdose therapy autologous stem cell transplantation ) . NOTE : If subject prior autologous stem cell transplant , must occur least three month prior screen subject must fully recover acute toxicity . Prior treatment Rituximab allow , provide complete least six month study enrollment . Male female â‰¥ 18 year age . Measurable evaluable disease . Predicted life expectancy least 12 week . ECOG Performance Status 0 1 . No chemotherapy , immunotherapy , hormonal therapy , biological therapy cancer , radiotherapy , surgical procedure ( except minor surgical procedure ) within four week begin treatment SB485232 ( 6 week nitrosoureas mitomycin C ) . Subjects must recover toxicity ( incur result previous therapy ) sufficiently enter Phase I study . A signed date write informed consent form obtain subject . The subject able understand comply protocol requirement , timetable , instruction protocolstated restriction . The subject likely maintain good venous blood access PK PD sample throughout study . A female eligible enter participate study : a. nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include female : hysterectomy , bilateral oophorectomy ( ovariectomy ) , bilateral tubal ligation , postmenopausal ( demonstrate total cessation menses great 1year ) , If amenorrheic less one year , postmenopausal status confirm serum follicle stimulate hormone ( FSH ) oestradiol concentration screen . , b. childbearing potential , negative serum pregnancy test Screen Visit , agree one follow GSK acceptable contraceptive method : intrauterine device ( IUD ) document failure rate le 1 % per year . vasectomized partner sterile prior female subject 's entry sole sexual partner female . oral contraceptive ( either combine progesterone ) . unacceptable failure rate barrier ( chemical and/or physical ) method , barrier method contraception must use combination acceptable method describe . Adequate organ function , Women pregnant breastfeeding . Significant cardiac , pulmonary , metabolic , renal , hepatic , gastrointestinal autoimmune condition opinion investigator and/or GSK medical monitor , place subject unacceptable risk participant trial . The subject diabetes mellitus poor glycemic control . The subject history human immunodeficiency virus ( HIV ) immunodeficiency disease . The subject positive Hepatitis B surface antigen . Corrected QT interval ( QTc ) &gt; 480msec . The subject history severe infusion relate reaction tumor lysis syndrome follow treatment Rituximab ( Section 10.2.2 ) . The subject circulate malignant cell count &gt; 25,000/mm3 peripheral blood . The subject know anaphylaxis IgEmediated hypersensitivity murine protein . The subject acute infection severe uncontrolled infection require systemic antibiotic therapy . Any serious medical psychiatric disorder would interfere subject safety inform consent . Known leptomeningeal disease evidence prior current metastatic brain disease . Routine screen central nervous system ( CNS ) image study ( CT MRI ) require clinically indicate . Receiving concurrent chemotherapy , immunotherapy , radiotherapy , investigational therapy . Oral corticosteroid within 14 day study entry . History alcohol abuse within six month screen alcohol consumption past six month exceed seven drinks/week woman 14 drinks/week men ( 1 drink = 5 ounce wine 12 ounce beer 1.5 ounce hard liquor ) . History ventricular arrhythmia require drug device therapy . Any unresolved unstable serious toxicity prior administration another investigational drug . Any investigational drug within 30 day five halflives ( whichever longer ) precede first dose SB485232 . Donation blood excess 500 mL within 56day period prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Rituximab ,</keyword>
	<keyword>oncology</keyword>
	<keyword>IL-18 ,</keyword>
	<keyword>combination study ,</keyword>
	<keyword>cytokine ,</keyword>
</DOC>